Gilead Sciences, Inc. $GILD Shares Purchased by Achmea Investment Management B.V.

Achmea Investment Management B.V. lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.4% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 480,352 shares of the biopharmaceutical company’s stock after buying an additional 24,564 shares during the period. Gilead Sciences accounts for approximately 0.7% of Achmea Investment Management B.V.’s holdings, making the stock its 28th biggest position. Achmea Investment Management B.V.’s holdings in Gilead Sciences were worth $53,319,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Centaurus Financial Inc. increased its holdings in shares of Gilead Sciences by 20.1% in the 3rd quarter. Centaurus Financial Inc. now owns 6,992 shares of the biopharmaceutical company’s stock worth $776,000 after acquiring an additional 1,168 shares during the period. First Affirmative Financial Network boosted its holdings in Gilead Sciences by 8.1% during the third quarter. First Affirmative Financial Network now owns 3,672 shares of the biopharmaceutical company’s stock worth $408,000 after buying an additional 276 shares in the last quarter. Asset Dedication LLC boosted its position in shares of Gilead Sciences by 16.2% in the 3rd quarter. Asset Dedication LLC now owns 15,708 shares of the biopharmaceutical company’s stock valued at $1,744,000 after purchasing an additional 2,188 shares during the period. Faithward Advisors LLC grew its position in Gilead Sciences by 21.3% during the 3rd quarter. Faithward Advisors LLC now owns 2,255 shares of the biopharmaceutical company’s stock worth $250,000 after purchasing an additional 396 shares in the last quarter. Finally, Captrust Financial Advisors increased its holdings in shares of Gilead Sciences by 1.6% in the 3rd quarter. Captrust Financial Advisors now owns 1,908,126 shares of the biopharmaceutical company’s stock valued at $211,802,000 after purchasing an additional 29,500 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Arcellx / takeover-related coverage — reports note a Gilead-related takeover theme that drove a big one‑day move in a small biotech (Arcellx). M&A activity or strategic deals in cell therapy could be viewed positively for Gilead’s pipeline expansion and long-term growth prospects. This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
• Neutral Sentiment: Unusual options activity flagged by market scanners — Barchart/MSN highlighted Gilead among mega‑caps with unusual options flows, which can signal speculative interest or hedging by institutions but is ambiguous for directional bias. Monitor option volumes and put/call skew for confirmation. 2 Mega-Cap Nasdaq Stocks with Unusual Options Activity: What to Watch
• Negative Sentiment: Insider sale — Johanna Mercier sold 3,000 shares at an average $144.23 on Mar 16 (disclosed to the SEC). Insider selling can be interpreted negatively by investors even if part of routine diversification or pre-set plans. Insider Sale – Johanna Mercier (SEC Filing)
• Negative Sentiment: Insider sale — CFO Andrew D. Dickinson also sold 3,000 shares at an average $144.23 on Mar 16. A sale by the CFO can draw extra attention from investors and may weigh on sentiment in the near term. Insider Sale – Andrew D. Dickinson (SEC Filing)

Gilead Sciences Stock Performance

NASDAQ GILD opened at $144.40 on Wednesday. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $157.29. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. The company has a market capitalization of $179.26 billion, a price-to-earnings ratio of 21.33, a PEG ratio of 1.90 and a beta of 0.37. The stock has a fifty day simple moving average of $141.62 and a 200 day simple moving average of $127.41.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. During the same quarter in the prior year, the firm posted $1.90 EPS. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.3%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. Gilead Sciences’s payout ratio is presently 48.45%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Monday, March 16th. The shares were sold at an average price of $144.23, for a total transaction of $432,690.00. Following the transaction, the chief financial officer directly owned 179,191 shares of the company’s stock, valued at $25,844,717.93. The trade was a 1.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the completion of the sale, the insider owned 120,288 shares of the company’s stock, valued at approximately $18,577,278.72. This trade represents a 18.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 309,280 shares of company stock valued at $44,068,850 over the last ninety days. Company insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. UBS Group lifted their target price on shares of Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Royal Bank Of Canada increased their price target on shares of Gilead Sciences from $103.00 to $118.00 and gave the stock a “sector perform” rating in a research report on Wednesday, February 11th. Needham & Company LLC reissued a “buy” rating and issued a $170.00 target price on shares of Gilead Sciences in a report on Monday, February 23rd. Mizuho lifted their price objective on Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 18th. Finally, Citigroup reiterated a “buy” rating on shares of Gilead Sciences in a report on Friday, March 6th. Twenty-four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $157.62.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.